1 |
Maheshwari R K, Singh A K, Gaddipati J, Srimal R C (2006). Multiple biological activities of curcumin: a short review. Life Sci, 78, 2081-7.
DOI
|
2 |
Mannello F, Luchetti F, Falcieri E, Papa S (2005). Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis, 10, 19-24.
DOI
|
3 |
Martin D C, Ruther U, Sanchez-Sweatman O H, Orr F W, Khokha R (1996). Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene, 13, 569-76.
|
4 |
Montgomery A M, Mueller B M, Reisfeld R A, Taylor S M, DeClerck Y A (1994). Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res, 54, 5467-73.
|
5 |
Munshi H G, Wu Y I, Mukhopadhyay S, et al (2004). Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis. J Biol Chem, 279, 39042-50.
DOI
ScienceOn
|
6 |
Mylona E, Magkou C, Giannopoulou I, et al (2006). Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome. Breast Cancer Res, 8, 57.
|
7 |
Nagaraju G P, Aliya S, Zafar S F, et al (2012). The impact of curcumin on breast cancer. Integr Biol, (in press).
|
8 |
Overall C M, Lopez-Otin C (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer, 2, 657-72.
DOI
ScienceOn
|
9 |
Nagase H, Visse R, Murphy G (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res, 69, 562-73.
DOI
ScienceOn
|
10 |
Notoya M, Nishimura H, Woo J T, et al (2006). Curcumin inhibits the proliferation and mineralization of cultured osteoblasts. Eur J Pharmacol, 534, 55-62.
DOI
|
11 |
Pacheco M M, Mourao M, Mantovani E B, Nishimoto I N, Brentani M M (1998). Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis, 16, 577-85.
DOI
ScienceOn
|
12 |
Park J, Conteas C N. Anti-carcinogenic properties of curcumin on colorectal cancer. World J Gastrointest Oncol, 2, 169-76.
|
13 |
Park M J, Kim E H, Park I C, et al (2002). Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. Int J Oncol, 21, 379-83.
|
14 |
Perkins S, Verschoyle R D, Hill K, et al (2002). Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev, 11, 535-40.
|
15 |
Qi JH, Ebrahem Q, Moore N, et al (2003). A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med, 9, 407-15.
DOI
|
16 |
Philip S, Bulbule A, Kundu G C (2004). Matrix metalloproteinase-2: mechanism and regulation of NF-kappaB-mediated activation and its role in cell motility and ECM-invasion. Glycoconj J, 21, 429-41.
DOI
|
17 |
Przybylowska K, Kluczna A, Zadrozny M, et al (2006). Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat, 95, 65-72.
DOI
|
18 |
Pulukuri S M, Patibandla S, Patel J, Estes N, Rao J S (2007). Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene, 26, 5229-37.
DOI
|
19 |
Ranogajec I, Jakic-Razumovic J, Puzovic V, Gabrilovac J (2012). Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol, 29, 561-9.
DOI
ScienceOn
|
20 |
Ree A H, Florenes V A, Berg J P, et al (1997). High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res, 3, 1623-8.
|
21 |
Shishodia S, Chaturvedi M M, Aggarwal B B (2007). Role of curcumin in cancer therapy. Curr Probl Cancer, 31, 243-305.
DOI
|
22 |
Sintara K, Thong-Ngam D, Patumraj S, Klaikeaw N (2012). Curcumin attenuates gastric cancer induced by N-methyl-N-nitrosourea and saturated sodium chloride in rats. J Biomed Biotechnol, 915380.
|
23 |
Valente P, Fassina G, Melchiori A, et al (1998). TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer, 75, 246-53.
DOI
|
24 |
Stetler-Stevenson W G (2008). The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev, 27, 57-66.
DOI
|
25 |
Stetler-Stevenson W G, Seo D W (2005). TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med, 11, 97-103.
DOI
|
26 |
Sun J (2010). Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases Are Essential for the Inflammatory Response in Cancer Cells. J Signal Transuct.
|
27 |
Vizoso F J, Gonzalez L O, Corte M D, et al (2007). Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer, 96, 903-11.
DOI
|
28 |
Woo M S, Jung S H, Kim S Y, et al (2005). Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochem Biophys Res Commun, 335, 1017-25.
DOI
|
29 |
Yang C L, Liu Y Y, Ma Y G, et al (2012). Curcumin Blocks Small Cell Lung Cancer Cells Migration, Invasion, Angiogenesis, Cell Cycle and Neoplasia through Janus Kinase-STAT3 Signalling Pathway. PLoS One, 7, 37960.
DOI
|
30 |
Zhang Y G, Du J, Tian X X, Zhong Y F, Fang W G (2007). Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas. Chin Med J, 120, 1597-605.
|
31 |
Zheng S, Chen A (2004). Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J, 384, 149-57.
DOI
|
32 |
Bica C G, Da Silva L L, Toscani N V, et al (2010). Polymorphism (ALA16VAL) correlates with regional lymph node status in breast cancer. Cancer Genet Cytogenet, 196, 153-8.
DOI
|
33 |
Aggarwal B B, Banerjee S, Bharadwaj U, et al (2007). Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol, 73, 1024-32.
DOI
|
34 |
Baker E A, Bergin F G, Leaper D J (2000). Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg, 87, 1215-21.
DOI
ScienceOn
|
35 |
Baker E A, Stephenson T J, Reed M W, Brown N J (2002). Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol, 55, 300-4.
DOI
|
36 |
Brummer O, Athar S, Riethdorf L, et al (1999). Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch, 435, 566-73.
DOI
|
37 |
Choudhuri T, Pal S, Das T, Sa G (2005). Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem, 280, 20059-68.
DOI
|
38 |
Buck T B, Yoshiji H, Harris S R, Bunce O R, Thorgeirsson U P (1999). The effects of sustained elevated levels of circulating tissue inhibitor of metalloproteinases-1 on the development of breast cancer in mice. Ann N Y Acad Sci, 878, 732-5.
DOI
|
39 |
Chen A, Xu J, Johnson A C (2006). Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene, 25, 278-87.
|
40 |
Chirco R, Liu X W, Jung K K, Kim H R (2006). Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev, 25, 99-113.
DOI
|
41 |
Curran S, Dundas S R, Buxton J, et al (2004). Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res, 10, 8229-34.
DOI
|
42 |
Decock J, Hendrickx W, Drijkoningen M, et al (2007). Matrix metalloproteinase expression patterns in luminal A type breast carcinomas. Dis Markers, 23, 189-96.
DOI
ScienceOn
|
43 |
Forget M A, Desrosiers R R, Beliveau R (1999). Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol, 77, 465-80.
DOI
|
44 |
Dorai T, Dutcher J P, Dempster D W, Wiernik P H (2004). Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate, 60, 1-17.
DOI
|
45 |
Figueira R C, Gomes L R, Neto J S, et al (2009). Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer, 9, 20.
DOI
|
46 |
Finan K M, Hodge G, Reynolds A M, et al (2006). In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2. Lung Cancer, 53, 273-84.
DOI
|
47 |
Gao W, Chan J Y, Wei W I, Wong T S (2012). Anti-Cancer Effects of Curcumin On Head And Neck Cancers. Anticancer Agents Med Chem.
|
48 |
Jiang Y, Goldberg I D, Shi Y E (2002). Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene, 21, 2245-52.
DOI
ScienceOn
|
49 |
Huang M T, Lou Y R, Ma W, et al (1994). Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res, 54, 5841-7.
|
50 |
Iwasaki M, Nishikawa A, Fujimoto T, et al (2002). Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines. Gynecol Oncol, 85, 103-7.
DOI
ScienceOn
|
51 |
John A, Tuszynski G (2001). The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res, 7, 14-23.
DOI
ScienceOn
|
52 |
Kato Y, Yamashita T, Ishikawa M (2002). Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. Oncol Rep, 9, 565-9.
|
53 |
Khokha R (1994). Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst, 86, 299-304.
DOI
|
54 |
Kunnumakkara A B, Anand P, Aggarwal B B (2008). Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett, 269, 199-225.
DOI
|
55 |
Kim H J, Park C I, Park B W, Lee H D, Jung W H (2006). Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J, 47, 333-42.
DOI
|
56 |
Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J (2009). Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer, 9, 188.
DOI
ScienceOn
|
57 |
Kotzsch M, Farthmann J, Meye A, et al (2005). Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur J Cancer, 41, 2760-8.
DOI
|
58 |
Lee C W, Lin W N, Lin C C, et al (2006). Transcriptional regulation of VCAM-1 expression by tumor necrosis factor-alpha in human tracheal smooth muscle cells: involvement of MAPKs, NF-kappaB, p300, and histone acetylation. J Cell Physiol, 207, 174-86.
DOI
ScienceOn
|
59 |
Li H C, Cao D C, Liu Y, et al (2004). Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat, 88, 75-85.
DOI
|
60 |
Lin L, Wang P, Zhao X L (2012). Study on curcumin-induced apoptosis in ovarian cancer resistant cell lines COC1/DDP. Sichuan Da Xue Xue Bao Yi Xue Ban, 43, 335-9 (in Chinese).
|